Cyclophosphamide vs mycophenolate
Adverse effects: anaemia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: anaemia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
- Cyclophosphamide for connective tissue disease–associated interstitial lung disease 2018 · Cochrane Headline outcomes onlyOR 1.63 [0.65, 4.11]2 studies · 300 participantsLow